TY - JOUR
T1 - Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors
AU - Fogli, Stefano
AU - Del Re, Marzia
AU - Curigliano, Giuseppe
AU - van Schaik, Ron H.
AU - Lancellotti, Patrizio
AU - Danesi, Romano
PY - 2019/3
Y1 - 2019/3
N2 - CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization. The present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on specific class of drugs used in combination.
AB - CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization. The present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on specific class of drugs used in combination.
KW - Breast cancer
KW - CDK4/6 inhibitors
KW - Drug-drug interaction
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Treatment personalization
UR - http://www.scopus.com/inward/record.url?scp=85060353286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060353286&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2019.01.006
DO - 10.1016/j.ctrv.2019.01.006
M3 - Review article
C2 - 30685576
AN - SCOPUS:85060353286
VL - 74
SP - 21
EP - 28
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
ER -